Top Page
Genedrive
(LSE:GDR)
Genedrive (GDR) vs. iShares MSCI United Kingdom ETF (EWC)
Genedrive Business Overview & Revenue Model
Genedrive Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 764.00K | 501.00K | 55.00K | 49.00K | 687.00K |
| Gross Profit | 764.00K | 254.00K | -199.00K | -3.82M | -3.82M |
| EBITDA | -5.36M | -7.49M | -5.70M | -5.37M | -1.37M |
| Net Income | -5.23M | -7.08M | -5.15M | -4.67M | -691.00K |
Balance Sheet | |||||
| Total Assets | 2.81M | 6.80M | 4.51M | 6.62M | 4.88M |
| Cash, Cash Equivalents and Short-Term Investments | 1.18M | 5.19M | 2.60M | 4.59M | 2.57M |
| Total Debt | 0.00 | 19.00K | 241.00K | 16.00K | 119.00K |
| Total Liabilities | 1.38M | 1.44M | 2.47M | 1.01M | 1.28M |
| Stockholders Equity | 1.44M | 5.36M | 2.04M | 5.61M | 3.59M |
Cash Flow | |||||
| Free Cash Flow | -5.12M | -3.80M | -3.83M | -4.67M | -5.29M |
| Operating Cash Flow | -5.10M | -3.77M | -3.78M | -4.61M | -5.18M |
| Investing Cash Flow | -23.00K | 1.00K | -37.00K | 45.00K | 33.00K |
| Financing Cash Flow | 1.12M | 6.36M | 1.82M | 6.58M | -456.00K |
Genedrive Technical Analysis
Genedrive Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | £107.90M | 15.58 | 8.50% | ― | -1.43% | 28.57% | |
52 Neutral | £22.25M | -3.03 | -213.66% | ― | 39.88% | 81.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | £1.13B | -2.82 | -29.43% | ― | 22.03% | 20.01% | |
47 Neutral | £16.86M | -1.51 | -153.92% | ― | 90.42% | 79.21% | |
45 Neutral | £20.71M | -7.52 | -58.27% | ― | 37.39% | -126.19% | |
44 Neutral | £12.67M | -0.47 | 425.97% | ― | -4.48% | 61.09% |
Genedrive Corporate Events
Genedrive plc, a Manchester‑based pharmacogenetic testing specialist, develops and commercialises rapid, low‑cost point‑of‑care genetic tests that enable clinicians to tailor drug choice and dosage, with a focus on emergency care. Its Genedrive MT‑RNR1 ID Kit for neonatal intensive care and CYP2C19 ID Kit for stroke patients, both delivered via single‑use ambient‑stable cartridges on its own thermocycler platform, have been recommended by NICE for use across the UK NHS.
At a General Meeting held on 9 March 2026, shareholders of Genedrive plc passed all resolutions supporting its previously announced fundraising, paving the way for the admission of new subscription, placing, open offer and loan conversion shares to trading on 10 March. Following admission, the company will have 1,605,568,256 ordinary shares in issue, significantly enlarging its capital base and providing funding flexibility to pursue its commercial growth strategy in the point‑of‑care pharmacogenetics market.
The most recent analyst rating on (GB:GDR) stock is a Sell with a £1.00 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.
Genedrive plc, a UK-listed point-of-care pharmacogenetic testing specialist, focuses on rapid, low-cost genetic diagnostics that enable clinicians to tailor drug choice and dosage, with particular emphasis on emergency healthcare settings. The company’s key products are the Genedrive MT-RNR1 ID Kit, used to guide neonatal antibiotic use, and the Genedrive CYP2C19 ID Kit, both delivered via disposable, ambient-stable cartridges on its own thermocycler platform.
Genedrive has conditionally raised approximately £0.91 million through an open offer that was 60.7% taken up by qualifying shareholders, and an additional £0.35 million via further subscriptions from investors who could not fully participate in the earlier placing or offer. Including the firm and conditional subscriptions, placing, open offer, additional subscriptions and loan conversion, the company expects to raise £5.26 million before expenses—around £4.9 million net—subject to shareholder approval and admission of 515,964,264 new shares, which will take its total share count to 1,605,568,256.
Major shareholders David Nugent and Robert English have supported the enlarged fundraising, while CEO Dr. Gino Miele and CFO Russ Shaw participated in the open offer as related parties, with the board deeming their involvement fair and reasonable following adviser consultation. The strengthened capital base is intended to support execution of Genedrive’s strategy in point-of-care pharmacogenetics, potentially reinforcing its market position and providing additional runway to commercialise its testing platform and expand uptake of its flagship kits.
The most recent analyst rating on (GB:GDR) stock is a Sell with a £1.00 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.
Genedrive has completed a placing of 50,000,000 new shares at 1.0 pence each, raising gross proceeds of £500,000 as part of a wider fundraising package that also includes a proposed £3.5 million direct subscription and an open offer of up to approximately £1.5 million to existing shareholders. The fundraising, largely conditional on shareholder approval at an early March general meeting and on admission of the new shares to trading on AIM, will significantly expand the company’s share capital and offers existing investors a chance to participate, while the detailed timing and terms of the open offer will be set out in a forthcoming circular.
The most recent analyst rating on (GB:GDR) stock is a Sell with a £1.00 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.
Genedrive plc plans to raise up to £5.5 million through a combination of a direct subscription, a conditional placing and an open offer to existing shareholders, all priced at 1.0 pence per new share, a 7.4% discount to the latest closing price. The largest and a significant shareholder will subscribe for up to £3.5 million, while the CEO and CFO intend to participate via the open offer, and a £500,000 shareholder loan will be converted to equity upon completion, releasing a debenture over the company’s assets.
The funds will be used to accelerate commercial rollout and market expansion in the UK, Europe and the Middle East, support an FDA 510(k) submission for its CYP2C19 test around June 2026, scale manufacturing, improve product usability and extend its IP into a laboratory-based CYP2C19 assay. Management warns that if only the firm subscription completes, cash runway extends only into March 2026, underscoring the importance of shareholder approval and full take-up of the conditional elements of the fundraising for the company’s going-concern position and growth plans.
The most recent analyst rating on (GB:GDR) stock is a Sell with a £1.00 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.
Genedrive plc has secured strong indicated backing from its largest shareholder David Nugent and significant shareholder Robert English for an equity financing of up to £6 million, with each committing to subscribe £1.5 million and Nugent planning to convert a recent £500,000 loan into equity while keeping his stake below 30%. The planned fundraising, which is expected to include an institutional placing and an open offer of up to £2 million to existing shareholders, will support the company’s commercial expansion in the UK, Europe and the Middle East, fund an FDA 510(k) submission for its CYP2C19 test, scale up manufacturing, refine product usability and extend its CYP2C19 technology to a laboratory platform, signalling strengthened financial support and strategic momentum behind its growth plans.
The most recent analyst rating on (GB:GDR) stock is a Sell with a £0.85 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.
Genedrive plc, a UK-based specialist in point-of-care pharmacogenetic testing for emergency and personalised medicine, has built a product suite around its Genedrive MT-RNR1 ID Kit for rapid antibiotic decision-making in neonatal intensive care and its CYP2C19 ID Kit for guiding antiplatelet choice in stroke patients, both backed by UK NICE recommendations and designed for rapid, on-site use without cold-chain logistics as part of a broader growth strategy in domestic and international healthcare markets. At its latest Annual General Meeting, all resolutions proposed to shareholders were duly passed with strong, though not unanimous, support across the proxy votes, reinforcing the company’s governance agenda and providing a mandate for management to continue executing its commercial and strategic plans in the pharmacogenetic testing space.
The most recent analyst rating on (GB:GDR) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.
Genedrive PLC announced the initiation of a ‘test of change’ pilot program in NHS Grampian and NHS Western Isles to utilize its CYP2C19 ID Kit for stroke patients in remote and rural areas. The pilot is supported by Scotland’s Centre for Sustainable Delivery and aims to evaluate the impact of rapid genetic testing on treatment outcomes, potentially paving the way for widespread adoption across Scotland. The initiative highlights Genedrive’s leadership in pharmacogenetic testing and its commitment to enhancing healthcare accessibility and precision, especially for underserved regions.
The most recent analyst rating on (GB:GDR) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.
Genedrive plc has launched an interactive investor hub aimed at enhancing communication with shareholders and stakeholders. This platform allows users to engage directly with the company, submit questions, and receive updates, thereby fostering transparency and direct dialogue. The initiative is part of Genedrive’s strategy to maintain open communication in a fast-paced environment, ensuring that investors have a reliable source for company updates and insights.
The most recent analyst rating on (GB:GDR) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.